Medicine
Stimufend 6 mg/0.6 mL injection
Stimufend 6 mg/0.6 mL injection is a prescription medicine containing Pegfilgrastim for subcutaneous use, marketed by Fresenius Kabi, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated between 36°F to 46°F (2°C to 8°C) in the carton to protect…
Key facts
- Active ingredient (INN)
- Pegfilgrastim
- Brand
- Stimufend
- Strength
- 6 mg/0.6 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 blister pack of 0.6 mL
- Marketing authorisation holder
- Fresenius Kabi
- Manufacturers
- Fresenius KabiNorthStar Rx
- Origin register
- US FDA, United States
- Storage
- Store refrigerated between 36°F to 46°F (2°C to 8°C) in the carton to protect from light. Do not freeze. Discard syringes stored at room temperature for more than 72 hours. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L03AA13 Pegfilgrastim
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 October 2022
- Identifiers
- RxCUI 2613763, 2613769DailyMed set ID b44bcb82-7e60-4dab-a658-115bdf5c053c, 1e36ee55-7f13-41db-9d49-2f7a92f3b750NDC 65219-371, 72603-402Application BLA761173
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 1 syringe in 1 blister pack / .6 mL in 1 syringe | 65219-371-10 | Fresenius Kabi | 6 October 2022 |
| 1 blister pack in 1 carton / 1 syringe in 1 blister pack / .6 mL in 1 syringe | 72603-402-01 | Northstar RX | 29 December 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Pegfilgrastim 6 mg/0.6 mL injection.
- Udenyca 6 mg/0.6 mL injectionAvailable on requestCoherus OncologyUS FDA6 packs Cold chain
- Armlupeg 6 mg/0.6 mL injectionAvailable on requestLupinIndiaUS FDA1 pack Cold chain
- Fulphila 6 mg/0.6 mL injectionAvailable on requestBiocon BiologicsIndiaUS FDA1 pack Cold chain
- Fylnetra 6 mg/0.6 mL injectionAvailable on requestAmneal PharmaceuticalsUS FDA1 pack Cold chain
- Neulasta 6 mg/0.6 mL injectionAvailable on requestAmgenUS FDA1 pack Cold chain
- Nyvepria 6 mg/0.6 mL injectionAvailable on requestPfizer LaboratoriesUS FDA1 pack Cold chain
Other strengths and forms of Pegfilgrastim
Clinical summary
Pegfilgrastim is a leukocyte growth factor indicated in adult and pediatric patients to Decrease the incidence of infection, as manifested by febrile neutropenia, among other approved uses. It is available as injection and kits for subcutaneous use. MedsAcross supplies Pegfilgrastim for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PegfilgrastimFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Neulasta prescribing information (Amgen) · U.S. National Library of Medicine, DailyMed
- Neulasta: European public assessment report (EPAR) · European Medicines Agency
- Cavoley: European public assessment report (EPAR) · European Medicines Agency
Need Stimufend 6 mg/0.6 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.